Page 75 - JCTR-11-3

Journal of Clinical and
Translational Research N-NOSE: Early cervical cancer screening

chemosensation strategy for the early detection of cancer 32. Asai A, Konno M, Ozaki M, et al. Scent test using
metabolites in urine samples. Sci Rep. 2021;11(1):17133. Caenorhabditis elegans to screen for early-stage pancreatic
doi: 10.1038/s41598-021-96613-z cancer. Oncotarget. 2021;12(17):1687.
22. Inaba S, Shimozono N, Yabuki H, et al. Accuracy evaluation doi: 10.18632/oncotarget.28035
of the C. elegans cancer test (N-NOSE) using a new combined 33. Ungkulpasvich U, Hatakeyama H, Hirotsu T, Di Luccio E.
method. Cancer Treat Res Commun. 2021;27:100370. Pancreatic cancer and detection methods. Biomedicines.
doi: 10.1016/j.ctarc.2021.100370 2023;11(9):2557.
23. Kusumoto H, Tashiro K, Shimaoka S, et al. Efficiency doi: 10.3390/biomedicines11092557
of gastrointestinal cancer detection by nematode-nose 34. Rengarajan S, Hallem EA. Olfactory circuits and behaviors
(N-NOSE). In Vivo. 2020;34(1):73-80. of nematodes. Curr Opin Neurobiol. 2016;41:136-148.
doi: 10.21873/invivo.11747 doi: 10.1016/j.conb.2016.09.002
24. Hatakeyama H, Morishita M, Alshammari AH, et al. A non- 35. Varshney LR, Chen BL, Paniagua E, Hall DH, Chklovskii DB.
invasive screening method using caenorhabditis elegans Structural properties of the Caenorhabditis elegans neuronal
for early detection of multiple cancer types: A prospective network. PLoS Comput Biol. 2011;7(2):e1001066.
clinical study. Biochem Biophys Rep. 2024;39:101778.
doi: 10.1371/journal.pcbi.1001066
doi: 10.1016/j.bbrep.2024.101778
36. Bian J, Zhang H, Meng S, Liu Y. Chemotaxis of toward
25. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda volatile organic compounds from induced by amino acids.
system: Terminology for reporting results of cervical J Nematol. 2018;50(1):3-8.
cytology. JAMA. 2002;287(16):2114-2119.
doi: 10.21307/jofnem-2018-003
doi: 10.1001/jama.287.16.2114
37. Thompson M, Sarabia Feria N, Yoshioka A, et al.
26. Bertero L, Massa F, Metovic J, et al. Eighth edition of the A Caenorhabditis elegans behavioral assay distinguishes
UICC classification of malignant tumours: An overview of the early stage prostate cancer patient urine from controls. Biol
changes in the pathological tnm classification criteria-what Open. 2021;10(3):bio057398.
has changed and why? Virchows Arch. 2018;472:519-531.
doi: 10.1242/bio.057398
doi: 10.1007/s00428-017-2276-y
38. Archiv V, Burns JS, Manda G. Metabolic pathways of the
27. Yoshida K, Hirotsu T, Tagawa T, et al. Odour Concentration-
dependent olfactory preference change in C. elegans. Nat warburg effect in health and disease: Perspectives of choice,
Commun. 2012;3(1):739. chain or chance. Int J Mol Sci. 2017;18(12):2755.
doi: 10.1038/ncomms1750 doi: 10.3390/ijms18122755
28. Bargmann CI, Hartwieg E, Horvitz HR. Odorant-selective 39. Liberti MV, Locasale JW. The Warburg effect: How does it
genes and neurons mediate olfaction in C. elegans. Cell. benefit cancer cells? Trends Biochem Sci. 2016;41(3):211-218.
1993;74(3):515-527. doi: 10.1016/j.tibs.2015.12.001
doi: 10.1016/0092-8674(93)80053-H 40. Troemel ER, Kimmel BE, Bargmann CI. Reprogramming
29. Nygård M, Daltveit AK, Thoresen SØ, Nygård JF. Effect of an chemotaxis responses: Sensory neurons define olfactory
antepartum pap smear on the coverage of a cervical cancer preferences in C. elegans. Cell. 1997;91(2):161-169.
screening programme: A population-based prospective doi: 10.1016/S0092-8674(00)80399-2
study. BMC Health Serv Res. 2007;7:1-8.
41. Emery JD. The challenges of early diagnosis of cancer in
doi: 10.1186/1472-6963-7-10 general practice. Med J Aust. 2015;203(10):391-393.
30. Chidyaonga-Maseko F, Chirwa ML, Muula AS. doi: 10.5694/mja15.00527
Underutilization of cervical cancer prevention services in
low and middle income countries: A review of contributing 42. Cleophas TJ, Droogendijk J, Van Ouwerkerk BM. Validating
factors. Pan Afr Med J. 2015;21(1):231. diagnostic tests, correct and incorrect methods, new
developments. Curr Clin Pharmacol. 2008;3(2):70-76.
doi: 10.11604/pamj.2015.21.231.6350
doi: 10.2174/157488408784293697
31. Sato Y, Futamura M, Tanaka Y, et al. Clinical possibility
of caenorhabditis elegans as a novel evaluation tool for 43. Shin A, Choi KS, Jun JK, et al. Validity of fecal occult blood
esophageal cancer patients receiving chemotherapy: test in the national cancer screening program, Korea. PLoS
A prospective study. Cancers (Basel). 2023;15(15):3870. One. 2013;8(11):e79292.
doi: 10.3390/cancers15153870 doi: 10.1371/journal.pone.0079292

Volume 11 Issue 3 (2025) 69 doi: 10.36922/jctr.24.00080